Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH market and competition

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Apr 05, 2021 3:47pm

76 Views

Post# 32938567

RE:RE:RE:NASH market and competition

I think it would be better stated that "the oncology program potential MAY BE so much larger than NASH"

TH just started a phase I trial and dosed its first patient. It is hardly a lock that we will even have a cancer program a year from now.

jeffm34 wrote: That's why you license it out. Let someone else spend the time and money on it. The oncology program potential is so much larger than NASH.

scarlet1967 wrote: even so the opportunity is too big to give it a pass.